Penile Squamous Cell Carcinoma Clinical Trial
Official title:
Cabozantinib in Patients With Advanced Penile Squamous Cell Carcinoma (PSCC): an Open-label, Single-center, Phase 2, Single-arm Trial (CaboPen)
Cabozantinib in patients with advanced penile squamous cell carcinoma (PSCC): an open-label, single-center, phase 2, single-arm trial (CaboPen)
an open-label, single-center, phase 2, single-arm trial ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02837042 -
Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma
|
Phase 2 | |
Completed |
NCT01807546 -
Oral Rigosertib for Squamous Cell Carcinoma
|
Phase 2 | |
Recruiting |
NCT03774901 -
Maintenance Avelumab Immunotherapy in Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma
|
Phase 2 | |
Not yet recruiting |
NCT06353906 -
Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02496208 -
Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors
|
Phase 1 | |
Active, not recruiting |
NCT02834013 -
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
|
Phase 2 | |
Completed |
NCT06068998 -
Molecular Characterization of Penile Cancers in Developing Countries
|